Venclexta, decitabine, and gilteritinib for AML – pro
This is a combination regimen that included the drug Xospata, wihch is FDA approved as a single agent for relapsed or refractory disease only. I was able to find a phase II study. This phase 2 trial (NCT03404193) enrolled ND patients with AML>60 years and R/R patients >18 years. Patients needed to have ECOG performance status <=3. Patients with favorable-risk cytogenetics and prior Bcl-2 inhibitor exposure were excluded. Patients received decitabine 20mg/m2 IV for 10-days every 4–6 weeks for induction followed by decitabine for 5-days after CR/CRi. (not the case for this caoimant) The authors concluded that triplet therapy with FLT3i, venetoclax, and decitabine is safe and an excellent frontline option for older patients with ND FLT3mut AML, and effective for R/R AML.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 May 2;12(5):77.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 May 2;12(5):77.